Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Entropy Neurodynamics Ltd

ENP.AX ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

ASX · Healthcare · Biotechnology & Medical Research ·

Australia Micro Cap Analyst: N/A

Last Close

$0.03

▼ -4.88%

Market Cap $45.15M · Vol 1.58M

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$45.15M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

41.67

Momentum

Beta

1.55

vs Market

52W High

$0.03

5.33% below

52W Low

$0.02

62.31% above

Volume

1.58M

Avg 1.65M

P/B

7.31

Price-to-book

ROE

N/A

Return on equity

Free Float

69.69%

Public shares

Shariah Compliance8 STANDARDS

✗ Entropy Neurodynamics Ltd (ENP.AX) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ENP.AX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-4.88%

+8.33%

+21.88%

+25.81%

YTD

+18.18%

+331.05%

-90.91%

Financials & Valuation

TTM · Annual

Total Revenue	$1.43M
Net Income	$-3,368,899.00
Revenue Growth (YoY)	+27.34%
Gross Margin	100.00%
Operating Margin	-227.81%
Net Profit Margin	-235.86%
ROE	N/A
ROA · ROIC	-64.72% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	24.31
P/B	7.31
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	1.63B

Technical Indicators

50-Day SMA	$0.03
200-Day SMA	$0.02
RSI (14)	41.67
Beta	1.55
52-Week High	$0.03
52-Week Low	$0.02

Volume Today	1.58M
Avg Daily Volume (30D)	1.65M
Relative Volume	0.96x
Volatility (10D)	42.96
Volatility (30D)	34.60
Free Float	69.69%

Analyst Consensus

N/A

Current Price $0.03

Mean Target N/A

52W Low$0.02 52W High$0.03

Current

Target

$0.02 $0.03

Current Analyst target

· 0 analysts

Identifiers

ExchangeASX

FIGIBBG00MJ66TJ7

ISINAU0000433583

CountryAustralia

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

LONN.S Lonza Group AG +1.23% ONC BeOne Medicines AG +1.55% 068270.KS Celltrion, Inc. +1.75% ABVX Abivax SA +4.66% ABVX.PA Abivax SA +3.59%

Company Profile

Entropy Neurodynamics Limited, formerly Tryptamine Therapeutics Limited, is an Australia-based clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. The Company’s lead program, TRP-8803, is a proprietary formulation of IV infused psilocin (the active metabolite of psilocybin) with potential to alleviate numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe. The Company has completed a Phase 2a clinical trial for the treatment of binge eating disorder and for the treatment of fibromyalgia. Each of the studies is utilizing TRP-8802 (synthetic, oral psilocybin) to demonstrate clinical benefit in these indications.